Back to top

Image: Bigstock

Why You Shouldn't Bet Against Cheniere Energy (LNG) Stock

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is Cheniere Energy, Inc. (LNG - Free Report) . This is because this security in the Oil and Gas - Exploration and Production - United States space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Oil and Gas - Exploration and Production - United States space as it currently has a Zacks Industry Rank of 42 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Cheniere Energy is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Cheniere Energy, Inc. Price and Consensus

In fact, over the past month, current quarter estimates have risen from 26 cents per share to 28 cents per share, while current year estimates have risen from $1.89 per share to $1.91 per share. This has helped LNG to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position.  You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Cheniere Energy. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Cheniere Energy, Inc. (LNG) - free report >>

Published in